"FDA and EMA release collaborative AI framework for drug development" was originally created and published by Clinical Trials ...

In Darwinian terms, survival isn’t a matter of being the biggest, the fastest, or the strongest of the species, but instead ...

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...

AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...

Top of the list is that AIs must be human-centric by design and align with ethical values. They must be developed using a ...

The FDA’s new draft guidance on Bayesian methodology signals a shift toward more flexible, data-driven clinical trial designs, enabling sponsors to use prior data and adaptive approaches to improve ...

SAN FRANCISCO, Jan 13 () - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug ...

The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

EMA and FDA define ten principles for AI use in medicines – in response to growing pressure from the industry.

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has been honored with the Research and ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.